GRPR and pachyonychia congenita: In 2017, the GRPR-antagonist NeoBOMB1 (DOTA-AMA-DGA-[D-Phe6-His12-NHCH[CH(CH3)2]2]-BBN(6–14) (Figure 6, 7)), that had already shown promising preclinical and clinical results as diagnostic and therapeutic probe for PC, was also evaluated in a BC preclinical model (84).